{"entity":{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","aka":[],"tldr":"Leads China's largest cancer centre and has run the Chinese phase 3 trials that brought PD-1 antibodies into GI cancer.","summary":"Rui-Hua Xu is President of Sun Yat-sen University Cancer Center in Guangzhou, China's largest cancer centre, and Professor of Medical Oncology. A gastrointestinal oncologist, he has run the Chinese phase 3 trials that brought PD-1 antibodies into gastrointestinal cancer, including JUPITER-06 with toripalimab in oesophageal cancer and studies of camrelizumab in ESCORT-1st, fruquintinib and anti-EGFR therapy, establishing immunotherapy and targeted therapy for Chinese patients. His publications include the JUPITER-06 trial of toripalimab plus paclitaxel and cisplatin as first-line treatment for advanced oesophageal squamous cell carcinoma. His interests span colorectal, oesophageal and gastric cancer and immunotherapy.","asOf":"2026-09-08","links":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20RH%5BAuthor%5D%20Sun%20Yat-sen%20gastrointestinal"}],"tags":[],"related":[],"cancers":["esophageal","colorectal","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab","camrelizumab","fruquintinib"],"companies":[],"institutions":["sysucc"],"pathways":[],"terms":[],"trials":["escort-1st"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"role":"President, Sun Yat-sen University Cancer Center; Professor of Medical Oncology","institutionId":"sysucc","specialisms":["Gastrointestinal oncology","Colorectal cancer","Oesophageal and gastric cancer","Immunotherapy"],"profiles":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20RH%5BAuthor%5D%20Sun%20Yat-sen%20gastrointestinal"}],"papers":[{"title":"Toripalimab plus paclitaxel and cisplatin as first-line treatment for advanced oesophageal squamous cell carcinoma (JUPITER-06)","journal":"Cancer Cell","year":2022,"doi":"10.1016/j.ccell.2022.02.007"},{"title":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPOTLIGHT+zolbetuximab+mFOLFOX6+Shitara+Lancet"}]},"route":"/people/xu-rui-hua/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"institution":[{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/"},{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/"}],"trial":[{"id":"escort-1st","kind":"trial","name":"ESCORT-1st","route":"/trials/escort-1st/"},{"id":"jupiter-06","kind":"trial","name":"JUPITER-06","route":"/trials/jupiter-06/"}],"journal":[{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/"}],"paper":[{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/"}]}}